Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin Lactobionate for Injection, USP

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™¥.

“We are very proud of the hard work of our team in gaining approval of this product,” said Usman Ahmed, Chief Operating Officer. “Bringing this product to market showcases Nexus’ commitment to ending drug shortages in the US and solving today’s critical healthcare challenges.”

Nexus Pharmaceuticals’ Erythromycin Lactobionate for Injection will be available in cartons of five single-dose vials.

About Erythromycin Lactobionate for Injection, USP

Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin.

For prescribing information, please see the following link.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art Wisconsin manufacturing facility, visit https://www.nexuspharma.net/project-tomorrow/.

¥ERYTHROCIN™ is a registered trademark of Pfizer Inc.